- New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the Sno 2026 Annual Meeting all eight treated patients alive, with median overall survival not reached, and a 100 objective response ra
Why Is DRTSW (DRTSW) Stock Up Today?
Updated Nov 21, 2026 6:51 PM ET ยท Prev Close $1.54
Session Regime & Catalyst Assessment
68% Signal ConvictionDrtsw Advancing 4.55% on 0.81x Relative Volume
Drtsw (Drtsw) is advancing 4.55% (+$0.07) to $1.61 on 0.81x average session volume. Relative to benchmarks, DRTSW is outperforming the S&P 500 by +8.19%. 14-day RSI stands at 30.6, keeping momentum in a bearish regime.
- New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the Sno 2026 Annual Meeting all eight treated patients alive, with median overall survival not reached, and a 100 objective response ra
Price ($1.61) trades relative to 20-day SMA ($2.81) and 50-day SMA ($3.40).
Market & Sector Relative Strength
DRTSW outperforming the S&P 500 by +8.19%Recent DRTSW Catalyst Headlines
Verified WireAlpha Tau Medical reported positive interim data from its U.S. REGAIN trial in recurrent glioblastoma, with five of six evaluable patients reaching complete response at the treated site and no unanticipated serious safet
Alpha Tau Medical Ltd. Nasdaq Drts on Sunday reported positive interim results from its U.S. REGAIN trial evaluating Alpha DaRT therapy in patients with recurrent glioblastoma.The data capture patient outcomes through No
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026 median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment range 3.1 to 11.6 mont
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.90 (session resistance) for directional breakout confirmation.
Technical Regime (DRTSW)
BEARISH MA TRENDRetail & Crowd Sentiment
NeutralAbout DRTSW
Get Instant DRTSW Catalyst Alerts
Receive an email alert when DRTSW triggers an unusual volume breakout, options sweep, or rating shift.
DRTSW Session & Catalyst FAQ
Why is DRTSW stock up today?
Drtsw (Drtsw) is advancing 4.55% (+$0.07) to $1.61 on 0.81x average session volume. Relative to benchmarks, DRTSW is outperforming the S&P 500 by +8.19%. 14-day RSI stands at 30.6, keeping momentum in a bearish regime.
Is DRTSW stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.81x relative volume (low participation). Our multi-factor model currently rates DRTSW as HOLD. Review full valuation, quality, and timing signals on the DRTSW Buy or Sell Decision Brief โ
What is DRTSW's intrinsic value and expected trading range?
At $1.61, DRTSW's modeled 1-to-3 session range is $1.52 โ $1.70, with a key inflection level at $1.90 (session resistance). Compare current price against multi-year cash flow projections in the DRTSW Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for DRTSW?
RSI at 30.6 reflects soft below-midline momentum. DRTSW trades at $1.61 relative to its 20-day SMA ($2.81) and 50-day SMA ($3.40), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.